Serum infliximab levels and clinical response in hidradenitis suppurativa
Serum infliximab levels and clinical response in hidradenitis suppurativa
About this item
Full title
Author / Creator
Publisher
Madrid: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Madrid: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Infliximab (IFX) is a chimeric immunoglobulin G‐1κ monoclonal antibody that neutralises the biologic activity of tumour necrosis factor‐α, and has shown efficacy (off‐label) for the treatment of severe hidradenitis suppurativa (HS). The relationship between clinical response and IFX pharmacokinetics (PK) in HS is currently unknown.
Alternative Titles
Full title
Serum infliximab levels and clinical response in hidradenitis suppurativa
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5023272012534ed2bade94e57763d475
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5023272012534ed2bade94e57763d475
Other Identifiers
ISSN
2768-6566
E-ISSN
2768-6566
DOI
10.1002/jvc2.139
